What is the 13F Pro Quality Score for TVRD?

13F Pro ranks Tvardi Therapeutics, Inc. (TVRD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TVRD's current score at https://13fpro.ai/research/TVRD (free sign-up required for the full ranking).

Which hedge funds own the most TVRD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TVRD include Slate Path Capital, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TVRD as soon as new 13F filings post.

Where does 13F Pro source TVRD data?

All Tvardi Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tvardi Therapeutics, Inc. files with the SEC under CIK 1346830. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TVRD in?

Tvardi Therapeutics, Inc. (TVRD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TVRD research updated on 13F Pro?

TVRD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tvardi Therapeutics, Inc.(TVRD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1346830 TVRD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TVRD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tvardi Therapeutics, Inc. (TVRD), a Healthcare sector company. TVRD is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Tvardi Therapeutics, Inc. reports net income of $-6.8M, free cash flow of $-5.9M. Top institutional holders of TVRD by reported 13-F value include Slate Path Capital, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TVRD trades on the Nasdaq exchange and files with the SEC under CIK 1346830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tvardi Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-6.8M

Free Cash Flow

Q1 2026

$-5.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-8.9% YoY

$21.0MFY 2023

FY19 $19.9MFY20 $135.1MFY21 $23.0MFY23 $21.0M

Net Income

+86.6% YoY

$-11.8MFY 2023

FY19 $-106.4MFY20 $8.4MFY21 $-88.4MFY23 $-11.8M

Operating Income

-36.4% YoY

$-121.5MFY 2023

FY19 $-111.7MFY20 $5.4MFY21 $-89.1MFY23 $-121.5M

EPS (Diluted)

-151.5% YoY

$-4.38FY 2023

FY19 $-2.49FY20 $0.18FY21 $-1.74FY23 $-4.38

Total Assets

-49.1% YoY

$125.8MFY 2023

FY19 $233.0MFY20 $271.2MFY21 $247.1MFY23 $125.8M

Op. Cash Flow

-53.2% YoY

$-92.1MFY 2023

FY19 $-109.2MFY20 $-5.5MFY21 $-60.1MFY23 $-92.1M

Metric	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$21.0M -8.9%	$23.0M -83.0%	$135.1M +579.3%	$19.9M +47.6%	$13.5M +1378.5%	$911.0K
Net Income	$-11.8M +86.6%	$-88.4M -1151.6%	$8.4M +107.9%	$-106.4M -43.7%	$-74.0M -27.3%	$-58.1M
Operating Income	$-121.5M -36.4%	$-89.1M -1754.3%	$5.4M +104.8%	$-111.7M -44.3%	$-77.4M -30.1%	$-59.5M
EPS (Diluted)	$-4.38 -151.5%	$-1.74 -1066.7%	$0.18 +107.2%	$-2.49 -20.9%	$-2.06	—
Total Assets	$125.8M -49.1%	$247.1M -8.9%	$271.2M +16.4%	$233.0M +22.1%	$190.8M +96.7%	$97.0M
Operating Cash Flow	$-92.1M -53.2%	$-60.1M -995.1%	$-5.5M +95.0%	$-109.2M -389.8%	$-22.3M +59.3%	$-54.8M

AI Insight: TVRD Financial Trends

Tvardi has stabilized operating losses near -$7M per quarter, but equity erosion from $33M to $15M in three quarters signals a tightening cash runway.

• Operating losses narrowed from -$17M in Q2 2024 to a range of -$6M to -$8M across Q3 2025–Q1 2026, suggesting cost discipline.

• Equity has declined from $33M in Q2 2025 to $15M in Q1 2026, falling $18M in three consecutive quarters.

• Operating cash outflows have moderated: Op CF improved from -$14M in Q3 2024 to -$4M to -$6M range in recent quarters.

• Revenue is absent in all four most recent quarters (Q2 2025–Q1 2026), versus $1M–$3M reported in the prior four quarters.

⚠ Equity of $15M in Q1 2026 versus ~$6M quarterly cash burn implies fewer than three quarters of buffer without new financing.

⚠ Total debt data is absent across all periods — undisclosed leverage could materially worsen the balance sheet picture.

⚠ The Q4 2024 Op Income spike to $25M and Q3 2024 Net Income of $34M appear one-time; watch for any recurrence or explanation.

AI Insight: TVRD Ratio Trends

Tvardi Therapeutics shows deeply negative and rapidly deteriorating returns, with ROE plunging from -79.3% in Q3 2025 to -187.6% in Q1 2026.

• ROE deteriorated sharply from -79.3% in Q3 2025 to -138.9% in Q4 2025 and -187.6% in Q1 2026, signaling accelerating net losses.

• ROA collapsed from -56.7% in Q3 2025 to -90.7% in Q4 2025, reflecting deepening asset-level losses.

• Q2 2025 showed an anomalous positive ROE of 50.6% and ROA of 38.1%, a single-quarter outlier not sustained in subsequent periods.

⚠ ROE of -187.6% in Q1 2026 is the worst on record — worsening trajectory suggests cash burn may be accelerating unsustainably.

⚠ Operating margin and NPM remain almost entirely unreported; limited disclosure makes fundamental trend analysis difficult.

Get alerted when TVRD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tvardi Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TVRD

Slate Path Capital LP
$2.2M704,118 sh
BlackRock, Inc.
$1.2M388,075 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1M344,708 sh
AMERICAN FINANCIAL GROUP INC
$711.2K223,659 sh
GEODE CAPITAL MANAGEMENT, LLC
$580.0K182,339 sh
SILVERCREST ASSET MANAGEMENT GROUP LLC
$321.3K101,034 sh
STATE STREET CORP
$309.2K97,231 sh
RENAISSANCE TECHNOLOGIES LLC
$292.9K92,100 sh
MORGAN STANLEY
$231.8K72,894 sh
Duncan Williams Asset Management, LLC
$201.1K63,241 sh

Fund	Value	Shares
Slate Path Capital LP	$2.2M	704,118
BlackRock, Inc.	$1.2M	388,075
VANGUARD CAPITAL MANAGEMENT LLC	$1.1M	344,708
AMERICAN FINANCIAL GROUP INC	$711.2K	223,659
GEODE CAPITAL MANAGEMENT, LLC	$580.0K	182,339
SILVERCREST ASSET MANAGEMENT GROUP LLC	$321.3K	101,034
STATE STREET CORP	$309.2K	97,231
RENAISSANCE TECHNOLOGIES LLC	$292.9K	92,100
MORGAN STANLEY	$231.8K	72,894
Duncan Williams Asset Management, LLC	$201.1K	63,241

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TVRD on your watchlist

Track score changes the day Tvardi Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TVRD a good stock to buy?

13F Pro's AI-powered analysis of Tvardi Therapeutics, Inc. (TVRD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TVRD are available on the TVRD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TVRD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TVRD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tvardi Therapeutics, Inc.'s investment landscape.